Esketamine superior to extended-release quetiapine with respect to remission at week 8
Other benefits seen for improved maternal social support, infant-focused anxiety, and negative emotionality in infants
Higher baseline hsCRP predicts poorer weight loss but has no effect on depression severity
Independent association seen for genetic liability to ADHD with risk for anorexia nervosa; bidirectional link noted to major depressive disorder
Selective serotonin reuptake inhibitor treatment tied to lower risk for maternal mental health problems and child externalizing behaviors across early childhood
Significant benefit seen as early as eight days compared with placebo
Findings based on 41 studies with data for children younger than 13 years old
Risk higher for offspring exposed to paternal depressive disorders than depression defined by nonclinical symptom scale
Findings seen especially for depression and when using therapy-based interventions
MBIs recommended for anxiety symptoms and depression symptoms during and after cancer treatment